CAMP (Camp4 Therapeutics) Beneish M-Score: -3.06 (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAMP Camp4 Therapeutics Corp CAMP
8 GF Score
Price $4.49
! 4 Warning Signs
View Full Analysis

What is Camp4 Therapeutics Beneish M-Score?

Camp4 Therapeutics CAMP +0.67% 8 Beneish M-Score is -3.06 as of Aug. 22, 2026. GuruFocus rates CAMP with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 828 Biotechnology companies, Camp4 Therapeutics ranks better than 76.09% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.06 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Camp4 Therapeutics's Beneish M-Score or its related term are showing as below:

CAMP' s Beneish M-Score Range Over the Past 10 Years
Min: -3.24   Med: -1.62   Max: 2.84
Current: -3.06

During the past 4 years, the highest Beneish M-Score of Camp4 Therapeutics was 2.84. The lowest was -3.24. And the median was -1.62.


Camp4 Therapeutics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Camp4 Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camp4 Therapeutics Beneish M-Score Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beneish M-Score
0.00 0.00 0.00 -0.18

Camp4 Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.84 0.00 -0.18 -3.24 -3.06

CAMP vs ALEC, ORMP, PYXS: Beneish M-Score Comparison

For the Biotechnology subindustry, Camp4 Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camp4 Therapeutics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Camp4 Therapeutics's Beneish M-Score falls into.


CAMP
8GF Score
Camp4 Therapeutics Corp CAMP
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camp4 Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Camp4 Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.4601+0.528 * 1+0.404 * 0.3021+0.892 * 1.4021+0.115 * 0.3908
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7743+4.679 * -0.224162-0.327 * 1.0072
=-3.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Total Receivables was $0.22 Mil.
Revenue was 1.779 + 1.294 + 0.348 + 0.795 = $4.22 Mil.
Gross Profit was 1.779 + 1.294 + 0.348 + 0.795 = $4.22 Mil.
Total Current Assets was $90.03 Mil.
Total Assets was $93.43 Mil.
Property, Plant and Equipment(Net PPE) was $2.51 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.82 Mil.
Selling, General, & Admin. Expense(SGA) was $17.91 Mil.
Total Current Liabilities was $19.14 Mil.
Long-Term Debt & Capital Lease Obligation was $1.57 Mil.
Net Income was -33.53 + -18.331 + -40.284 + -15.099 = $-107.24 Mil.
Non Operating Income was -20.957 + -6.17 + -28.218 + -2.365 = $-57.71 Mil.
Cash Flow from Operations was -12.686 + -10.981 + 6.293 + -11.217 = $-28.59 Mil.
Total Receivables was $0.11 Mil.
Revenue was 1.497 + 0.858 + 0.652 + 0 = $3.01 Mil.
Gross Profit was 1.497 + 0.858 + 0.652 + 0 = $3.01 Mil.
Total Current Assets was $41.09 Mil.
Total Assets was $51.28 Mil.
Property, Plant and Equipment(Net PPE) was $8.57 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.69 Mil.
Selling, General, & Admin. Expense(SGA) was $16.50 Mil.
Total Current Liabilities was $7.34 Mil.
Long-Term Debt & Capital Lease Obligation was $3.95 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.217 / 4.216) / (0.106 / 3.007)
=0.051471 / 0.035251
=1.4601

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.007 / 3.007) / (4.216 / 4.216)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (90.027 + 2.507) / 93.428) / (1 - (41.086 + 8.565) / 51.275)
=0.009569 / 0.031672
=0.3021

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4.216 / 3.007
=1.4021

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.687 / (1.687 + 8.565)) / (1.823 / (1.823 + 2.507))
=0.164553 / 0.421016
=0.3908

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(17.91 / 4.216) / (16.498 / 3.007)
=4.248102 / 5.486531
=0.7743

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.57 + 19.142) / 93.428) / ((3.951 + 7.335) / 51.275)
=0.221689 / 0.220107
=1.0072

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-107.244 - -57.71 - -28.591) / 93.428
=-0.224162

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Camp4 Therapeutics has a M-score of -3.06 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.06 mean?
Camp4 Therapeutics (CAMP) has a Beneish M-Score of -3.06 as of Aug. 22, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Camp4 Therapeutics and its competitors. According to the industry distribution chart, Camp4 Therapeutics ranks #198 out of 828 companies in the Biotechnology industry, placing it in the top 23.9%.
Is Camp4 Therapeutics' Beneish M-Score too high?
Camp4 Therapeutics' current Beneish M-Score is -3.06. Based on the distribution chart, Camp4 Therapeutics ranks #198 out of 828 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camp4 Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Camp4 Therapeutics' Beneish M-Score compare to ALEC and ORMP?
According to the Biotechnology industry distribution chart, Camp4 Therapeutics ranks #198 out of 828 companies for Beneish M-Score. This places Camp4 Therapeutics in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Camp4 Therapeutics and its competitors. Camp4 Therapeutics's current Beneish M-Score is -3.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camp4 Therapeutics stock overvalued right now?
Camp4 Therapeutics (CAMP) has a current Beneish M-Score of -3.06. The current Beneish M-Score is -3.06. Camp4 Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Camp4 Therapeutics (CAMP), the current Beneish M-Score is -3.06 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Camp4 Therapeutics Business Description

Address One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA, 02139
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
8GF Score

Get the complete analysis for CAMP

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.49
Price